hepatitis B

Race for hepatitis B drug intensifies as Antios raises $96m for phase 2 trial
Race for hepatitis B drug intensifies as Antios raises $96m for phase 2 trial
Pharmaforum
Antios
funding
hepatitis B
ATI-2173
Flag link:
Drug Farm bags $56M to take novel hepatitis B drug into humans
Drug Farm bags $56M to take novel hepatitis B drug into humans
Fierce Biotech
Drug Farm
hepatitis B
funding
drug development
Flag link:
Gilead & Vir Announce Collaboration To Find Cure For Hepatitis B Virus
Gilead & Vir Announce Collaboration To Find Cure For Hepatitis B Virus
NASDAQ
Gilead Sciences
Vir Biotechnology
hepatitis B
clinical trials
Flag link:
Assembly Bio's hepatitis B program flops as a potential cure in PhII, sending shares spiraling
Assembly Bio's hepatitis B program flops as a potential cure in PhII, sending shares spiraling
Endpoints
Assembly Biosciences
hepatitis B
clinical trials
vebicorvir
Flag link:
New data from J&J, Arrowhead mark latest step in RNAi's hepatitis B race
New data from J&J, Arrowhead mark latest step in RNAi's hepatitis B race
BioPharma Dive
Arrowhead Pharmaceuticals
JNJ
clinical trials
RNAi
hepatitis B
Flag link:
J&J's RNAi suppresses hepatitis B for 48 weeks after last dose
J&J's RNAi suppresses hepatitis B for 48 weeks after last dose
Fierce Biotech
JNJ
RNAi
JNJ-3989
hepatitis B
Flag link:
Ionis deal delivers for GSK as HBV drug hits the mark in phase 2
Ionis deal delivers for GSK as HBV drug hits the mark in phase 2
Pharmaforum
GSK
antisense
hepatitis B
clinical trials
GSK3228836
Ionis Pharmaceuticals
Flag link:
EASL 2020 – Assembly finds a partner as hepatitis B inches forward
EASL 2020 – Assembly finds a partner as hepatitis B inches forward
EP Vantage
EASL
RNAi
hepatitis B
Assembly Biosciences
Abrutus
JNJ
GSK
Vir Biotechnology
Flag link:
Dicerna guides Roche-partnered hepatitis B drug past early test
Dicerna guides Roche-partnered hepatitis B drug past early test
Fierce Biotech
Roche
Dicerna Pharmaceuticals
hepatitis B
RG6346
clinical trials
Flag link:
Roche drops hep B antiviral as late-stage pipeline tests 'largely on track' despite COVID-19 disruption
Roche drops hep B antiviral as late-stage pipeline tests 'largely on track' despite COVID-19 disruption
Fierce Biotech
Roche
antiviral
hepatitis B
RG6217
Flag link:
BeiGene expands pipeline and hops on board a quest to cure hep B, inking a $540M deal with a fellow upstart biotech
BeiGene expands pipeline and hops on board a quest to cure hep B, inking a $540M deal with a fellow upstart biotech
Endpoints
China
BeiGene
Assembly Biosciences
hepatitis B
Flag link:
Biotech Gilead axes $445M Precision Biosciences gene therapy hep B pact
Biotech Gilead axes $445M Precision Biosciences gene therapy hep B pact
Fierce Biotech
Gilead Sciences
Precision Biosciences
hepatitis B
R&D
Flag link:
Is Arrowhead Pharmaceuticals Close to a Cure for HBV?
Is Arrowhead Pharmaceuticals Close to a Cure for HBV?
Motley Fool
Arrowhead Pharmaceuticals
hepatitis B
Flag link:
Vir reminds biopharma its original aim is hepatitis B
Vir reminds biopharma its original aim is hepatitis B
BioPharma Dive
Vir Biotechnology
hepatitis B
VIR-2218
clinical trials
Flag link:
Upcoming events – Soleno has a date with Destiny while Arbutus tries again
Upcoming events – Soleno has a date with Destiny while Arbutus tries again
EP Vantage
Solena
diazoxide choline
Prader-Willi Syndrome
Arbutus
hepatitis B
ARB-729
Flag link:
Patient dies in a troubled HBV drug program — forcing developers to scrap the drug and shift focus
Patient dies in a troubled HBV drug program — forcing developers to scrap the drug and shift focus
Endpoints
hepatitis B
Spring Bank Pharmaceuticals
clinical trials
patient deaths
inarigivir soproxil
Flag link:
Spring Bank Pharma shares slide 45% premarket after it halts trial of treatment for hepatitis B virus
Spring Bank Pharma shares slide 45% premarket after it halts trial of treatment for hepatitis B virus
Marketwatch
Spring Bank Pharmaceuticals
hepatitis B
clinical trials
FDA
inarigivir soproxil
Flag link:
AASLD 2019 – Assembly asks investors to keep the faith
AASLD 2019 – Assembly asks investors to keep the faith
EP Vantage
AASLD
Assembly Biosciences
hepatitis B
ABI-H0731
Flag link:
Roche pays $200M for rights to Dicerna's hepatitis B RNAi drug
Roche pays $200M for rights to Dicerna's hepatitis B RNAi drug
Fierce Biotech
Roche
Dicerna Pharmaceuticals
RNAi
hepatitis B
DCR-HBVS
Flag link:
Two acute cases of liver disease in healthy subjects kill Arbutus' hep B program
Two acute cases of liver disease in healthy subjects kill Arbutus' hep B program
Endpoints
Arbutus BioPharma
hepatitis B
clinical trials
Vivek Ramaswamy
AB-506
Flag link:

Pages